Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Following dramatic success in many types of advanced solid tumors, interest in
immunotherapy for the treatment of colorectal cancer (CRC) is increasingly growing. Given …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a …

Colorectal cancer (CRC) is highly heterogeneous at the genetic and molecular level, which
has major repercussions on the efficacy of immunotherapy. A small subset of CRCs exhibit …

Metastatic colorectal cancers (mCRCs) are clinically heterogeneous, but the genomic basis
of this variability remains poorly understood. We performed prospective targeted sequencing …

Genomic instability remains an enabling feature of cancer and promotes malignant
transformation. Alterations of DNA damage response (DDR) pathways allow genomic …

Defects in pathways governing genomic fidelity have been linked to improved response to
immune checkpoint blockade therapy (ICB). Pathogenic POLE/POLD1 mutations can cause …